Golodirsen: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Golodirsen. Educational only — not medical advice.

Labeled uses

VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53 [see Clinical Studies (14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Source: FDA labeling via NIH DailyMed (set 35c227d1…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.